Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medicago Inc MDCGF

GREY:MDCGF - Post Discussion

Medicago Inc > seniors moment
View:
Post by Indicator on Apr 09, 2012 10:22pm

seniors moment

I was having a Seniors moment ;-)
No wonder I could not replicate it today - my excerpt from Ricky's post, not from a press release:

https://www.stockhouse.com/Bullboards/MessageDetail.aspx?p=0&m=30915237&l=0&r=0&s=MDG&t=LIST

Ricky, where do you get this article from? Here's a rough English translation - the juicy bit is at the end:

"Crossing the desert has been painful for many biotechs in Quebec, some tragic, died of thirst along the way. Arriving at the oasis is no less real for others.

Vaccinated by tobacco

Medicago, Quebec is one of those who are drinking in deep financial pit. March 6, it announced an agreement with Mitsubishi Tanebe (MT), a Japanese pharma founded in 1997 after a cascade of mergers and acquisitions. The agreement provides for an initial payment of 33 million to Medicago. MT is a medium-sized pharma announced a net profit of $ 400 000 Canadian in the last quarter.

"This is just the beginning, warns Andy Sheldon, President of Medicago. This is a payment for the first of three projects that we have with MT. It is for us to produce, with our original technology, vaccines in industrial quantities that will then distribute MT. The 33 million are not used to cover the costs of development and production. This is a pure income. Fees will be paid by MT in addition to the payment of 33 million. "

Medicago must convince ordinary tobacco plants to produce viral like particles and encapsulate the course of a lipid micro capsule. The Quebec company has mastered this kind of acrobatics biotechnology. In this case, it is to produce a pseudo rotavirus to serve as vaccine against infant diarrhea, an infection that made terrible havoc in Asia and Africa. Two other vaccines are in development following the agreement with MT. If efforts are successful, similar to the first payments are scheduled.

Medicago faces another technical challenge and this in record time. "The Defense Advanced Research Projects Agency-(DARPA) U.S. urges us to take up the gauntlet in what will be an exciting sprint enough, says Mr Sheldon. This is to produce 10 million doses of a vaccine that I can not say much, by the end of March! "

The nature of the vaccine is kept secret because DARPA's mission is technologically ahead of the enemies of the United States in a potential bacteriological typing.

Comment by rickydee on Apr 10, 2012 6:50am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities